Zacks Investment Research upgraded shares of Nabriva Therapeutics (NASDAQ:NBRV) from a hold rating to a buy rating in a research report report published on Tuesday, Zacks.com reports. Zacks Investment Research currently has $2.75 price target on the biotechnology company’s stock.
According to Zacks, “Nabriva Therapeutics is a biopharmaceutical company engaged in the research and development of new medicines to treat serious bacterial infections, with a focus on the pleuromutilin class of antibiotics. Nabriva Therapeutics’ medicinal chemistry expertise has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations. Nabriva Therapeutics’ lead product candidate, lefamulin, is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. The company believes that lefamulin is the first antibiotic with a novel mechanism of action to have reached late-stage clinical development in more than a decade. Nabriva has announced positive topline data for lefamulin from the first of its two global, registrational Phase 3 clinical trials evaluating lefamulin in patients with moderate to severe community-acquired bacterial pneumonia (CABP). “
Several other analysts have also recently issued reports on NBRV. Needham & Company LLC reissued a buy rating and issued a $10.00 target price (down from $15.00) on shares of Nabriva Therapeutics in a research note on Wednesday, May 1st. ValuEngine lowered shares of Zosano Pharma from a buy rating to a hold rating in a report on Wednesday, May 1st. BidaskClub lowered shares of Zebra Technologies from a hold rating to a sell rating in a report on Friday, May 24th. Northland Securities set a $13.00 price objective on shares of Nabriva Therapeutics and gave the stock a buy rating in a report on Wednesday, May 8th. Finally, Gabelli restated a buy rating on shares of Flushing Financial in a report on Thursday, May 2nd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and an average price target of $7.34.
Nabriva Therapeutics (NASDAQ:NBRV) last posted its earnings results on Friday, May 10th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.32) by $0.03. The company had revenue of $1.70 million for the quarter, compared to analysts’ expectations of $0.56 million. Nabriva Therapeutics had a negative return on equity of 119.75% and a negative net margin of 3,194.72%. On average, equities research analysts anticipate that Nabriva Therapeutics will post -1.14 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Jane Street Group LLC purchased a new position in shares of Nabriva Therapeutics during the fourth quarter valued at approximately $29,000. Fosun International Ltd purchased a new position in shares of Nabriva Therapeutics during the first quarter valued at approximately $1,593,000. FMR LLC lifted its holdings in shares of Nabriva Therapeutics by 514.2% during the fourth quarter. FMR LLC now owns 1,842,700 shares of the biotechnology company’s stock valued at $2,690,000 after purchasing an additional 1,542,700 shares during the last quarter. Two Sigma Advisers LP purchased a new position in shares of Nabriva Therapeutics during the fourth quarter valued at approximately $37,000. Finally, Paloma Partners Management Co purchased a new position in shares of Nabriva Therapeutics during the fourth quarter valued at approximately $54,000. Institutional investors and hedge funds own 3.02% of the company’s stock.
About Nabriva Therapeutics
Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.
Further Reading: Trading based on a resistance level
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.